Amari, Diana T.
Juday, Timothy
Frech, Feride H.
Wang, Weiying
Wu, Zheng
Atkins, Norman Jr.
Wickwire, Emerson M.
Funding for this research was provided by:
Eisai Incorporated
Article History
Received: 10 July 2021
Accepted: 23 May 2022
First Online: 4 June 2022
Declarations
:
: This study was determined by Advarra to be exempt from institutional review board review under the U.S. Department of Health and Human Services regulations (IRB # 2018–0054-GR-NJ). This study was conducted using an anonymous, publicly available secondary dataset that meets the US HIPPA requirement. Ethics approval and consent to participate are not applicable for the current study per US 45 Code of Federal Regulations Part 46, human participant protection regulations, and Protections of Human Subjects. This study was conducted in accordance with the principles of the Declaration of Helsinki and its later amendments.
: Not applicable.
: EMW received compensation for consulting on this study. EMW's institution has received research funding from the AASM Foundation, US DoD, Merck, ResMed and ResMed Foundation. EMW has served as a scientific consultant to DayZz, Eisai, Merck, and Purdue, and is an equity shareholder in WellTap. TJ, FF and NA are employees of Eisai, Inc. DTA, WW and ZW are employees of Genesis Research, which received compensation for conducting this study.